|
|
 |
|
Viewing report
|
|
|
|
Lung Cancer Drug Pipeline Update 2009
Bioseeker, Jan 2009
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. More than 80,000 new SCLC cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today more than 350 therapeutics targeting lung cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years amount to another 117 drugs. Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 181 different targets. These targets are further categorized on the CD-ROM by 55 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Lung Cancer Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
Find competitors, collaborations partners, M&A candidates etc.
Jump start competitive drug intelligence operations
Excellent starting point for world wide benchmarking
Compare portfolio and therapy focus with your peers
Speed up pro-active in-/out licensing strategy work
Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Investigators Includes more than 265 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.
Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.
Drug name & Synonyms Lists commercial, generic and code names for drugs. In all more than 500 names
Developmental stage This Drug Pipeline Update contains 352 drugs in active development for the treatment of lung cancer:
#37 marketed drugs
#1 drug registered
#3 drugs pre-registered
#22 drugs in Phase III
#140 drugs in Phase II
#76 drugs in Phase I
#63 drugs in Preclinical
#10 drugs in other developmental stages
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included lung cancer drugs are also in development for over 120 other listed indications
Note: You are able to sort and find drugs according to type of indication from drop-down menu in the application.
Targets Identified drugs are linked to more than 181 different targets, divided into 55 classifications of molecular function:
- Carboxy-lyase activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Complement activity
- Cysteine-type peptidase activity
- Cytokine activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-methyltransferase activity
- Extracellular ligand-gated ion channel activity
- Extracellular matrix structural constituent
- Glutathione transferase activity
- G-protein coupled receptor activity
- Growth factor activity
- GTPase activity
- Hormone activity
- Hydrolase activity
- Ion channel activity
- Kinase activity
- Kinase regulator activity
- Ligase activity
- Lipase activity
- Lipid kinase activity
- Metallopeptidase activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peptidase activity
- Peroxidase activity
- Phosphoric diester hydrolase activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- RNA binding
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
Identified targets are categorized into 23 different primary and alternate sub-cellular localizations:
- Centrosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Integral to membrane
- Lysosome
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Plasma membrane
- Secreted
- Secretory granule
Note: You are able to sort and find drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 204 protein expression profiles of 141 drug targets in various human tissues and cancer types, cell lines and primary cells, includin up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their invovlement in different cellular pathways, according to BioCarta, KEGG and NetPath.
- BioCarta 225 Pathways
- KEGG 68 Pathways
- NetPath 20 Signaling Pathways
Note: You are able to sort and find drugs according to targeted pathways from drop-down menues in the application.
Mechanism In total there are 217 different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to sort and find drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Drug Profile Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Investigator & Partners
Presentation of principal investigator and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol - Official Gene Name [Species/Homo Sapiens] - Molecular Function
Target Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.
Mechanism
Drug mechanism of action
Developmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma - Phase II Clinical Trial - Active
Cancer, prostate - Phase III Clinical Trial - Ceased
Drug Description
Short introduction to drug
Compound Data
Compound type, Chemical name, CAS Number and molecular weight
Patent Data
Available patent information related to the drug is presented here.
Business & Markets
Collaborations and deals
Approvals and submissions
Analyst comments
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Preclinical Data
Available preclinical development data, developmental history and scientific data.
Licensing Information
Availability for licensing
Application Features Use 13 different parameters, available in drop-down menus, to find and sort among drugs
- Drug status
- Clinical Trial Status
- Principle Investigator
- Partners
- Indication
- Developmental Stage
- Compound Type
- Mechanism
- Target
- Molecular Function of Target
- Target Localization
- Targeted Pathways
- Free text search of entire drug profile contents
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
- Direct links to company web pages of principal investigators
Export and sharing of information
- Found information is easily shared with others over e-mail, file export (xls) or in print
System Requirements - AMD-Athlon/Pentium II PC
- Windows 98/NT4/2000/ME/XP/VISTA
- 8x-speed CD Rom drive
- SVGA 16 bit display. (32 bit recommended)
- 32 MB of available RAM (128 MB recommended)
- Internet access (for related internet resources)
Customers who bought this item also bought
Analytical Tool - Current & Future Lung Cancer Therapeutics
Lung Cancer Drug Pipeline Update 2008
PharmaWatch: Cancer
Healthcare Review: Cancer - October 2002
The World Cancer Market Yearbook 2005
Marketwatch: Insight Into Key Events In The Cancer Industry
Update and Intensive Review of Internal Medicine
MDCT and MR Update: Body and Musculoskeletal Imaging
Antibodies in Oncology: Drug Pipeline Update 2008
Disruption or Advantage? Update on Companion Diagnostics
Medical Review Criteria Guidelines for Managing Care, 8th edition. (2009 Update)
Body Imaging: Abdominal, Thoracic and Vascular
|
|
|
|
